BASEL (dpa-AFX) - BeiGene, Ltd. (BGNE) announced the China National Medical Products Administration or NMPA has granted approval to the company's anti-PD-1 antibody, tislelizumab, as a treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma who have disease progression or are intolerant to first-line standard chemotherapy. The approval was supported by results from a randomized, open-label, multi-center, global phase 3 clinical trial, RATIONALE 302.
Tislelizumab is also under regulatory review in the U.S. and the European Union, submitted by Novartis in their licensed territories.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2022 AFX News